Nuvation Bio Inc. (NUVB) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-33.1%

$3.12

vs $4.67 price

Levered DCF

$1.24

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

0.52

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-14.93×	-1.26×	-4.31×	-4×	-19.32×	-61.58×	-62.5×	-1,851.85×
P/B	10.01×	1.54×	0.55×	0.64×	2.25×	11.84×	17.55×	-2,469.57×
P/S	48.65×	90.81×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-15.36×	-1.21×	-3.86×	-3.07×	-17.92×	-60.56×	-64.3×	0×
Gross margin	86.6%	10.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-338.7%	-7527.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-325.3%	-7213.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	6.95×	9.04×	44.11×	50.7×	45.62×	33.69×	37.42×	0.18×
Debt / equity	0.03×	0.02×	0.01×	0.01×	0×	0×	0×	-0.81×
Interest coverage	-15.57×	-1,737.91×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-66.9%	-122.5%	-12.5%	-15.9%	-11.6%	-19.4%	-28.5%	133.3%
Return on invested capital	-41.0%	-120.9%	-16.4%	-18.1%	-12.3%	-20.2%	-27.3%	688.9%
Return on assets	-34.4%	-105.1%	-12.2%	-15.5%	-11.2%	-18.8%	-27.7%	-627.8%
Free cash flow yield	-5.7%	-18.3%	-20.6%	-23.2%	-4.1%	-1.4%	-1.2%	-0.0%
Earnings yield	-6.7%	-79.4%	-22.9%	-25.0%	-5.2%	-1.6%	-1.6%	-0.1%
Enterprise value	$2.9B	$688.1M	$291.9M	$319.3M	$1.6B	$2.5B	$2.1B	$1.8B
Net debt / EBITDA	0.81×	0.05×	0.51×	0.93×	1.49×	0.72×	0.11×	0×
Cash conversion cycle (days)	196	428	0	0	0	-7,693	0	0